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O B J E C T I V E S The aim of the study was to determine the association of coronary computed
tomographic angiography (CTA)–identiﬁed coronary artery disease (CAD) with post-test aspirin, statin,
and antihypertensive medication use and changes in cholesterol and blood pressure (BP).
B A C KG ROUND The relationship of CTA ﬁndings to subsequent changes in preventive cardiovas-
cular medication prescribing patterns and risk factors is largely unknown.
METHOD S We studied 1,125 consecutive patients without known CAD referred for coronary CTA.
CAD was deﬁned as none, nonobstructive (50%), or obstructive (50%). Prescriptions were queried in
the 6 months pre- and post-CTA for comparison of aspirin, statin, and BP treatment. Medication
intensiﬁcation was deﬁned as initiation, dose increase, or, for statins, change to a more potent
formulation. Lipid and BP values were obtained at 12 months pre- and post-CTA.
R E S U L T S Patients were 50 12 years of age (59% men), with 34%, 47%, and 33% on baseline statin,
BP medication(s), and aspirin, respectively. Relative to patients without CAD (n  617), patients with
nonobstructive (n  411) and obstructive CAD (n  97) demonstrated signiﬁcant intensiﬁcation in
unadjusted rates of statin (26%, 46%, and 46% of patients; p  0.001), BP (11%, 21%, and 24%; p 
0.001), and aspirin therapies (9%, 29%, and 40%; p  0.001), and signiﬁcant improvements in total
cholesterol (6.7,14.7, and24.7 mg/dl; p 0.008), low-density lipoprotein cholesterol (5.6,14.1,
and 24.6 mg/dl; p  0.001), systolic (0.1, 1.4, and 4.9 mm Hg; p  0.002), and diastolic BP (0.6,
1.0, and3.4 mm Hg; p 0.012), respectively. Adjusted for baseline risk factors and medications, CAD
was independently associated with increased aspirin, statin, and BP medication use rates in CTA-
identiﬁed nonobstructive CAD (odds ratio [OR]: 6.9, 95% conﬁdence interval [CI]: 4.7 to 10.2; OR: 6.6, 95%
CI: 3.0 to 14.3; OR: 1.6, 95% CI: 1.1 to 2.2, respectively; p  0.05), and aspirin and statin use in obstructive
CAD (OR: 42.4, 95% CI: 15.8 to 113.9; OR: 30.3, 95% CI: 3.2 to 289.2, respectively; p  0.05).
CONC L U S I O N S CAD presence and severity on CTA are associated with increased use of
preventive cardiovascular medications and improvements in cholesterol and BP. (J Am Coll Cardiol Img
2013;6:574–81) © 2013 by the American College of Cardiology Foundation
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575ignificant data have demonstrated that cor-
onary artery disease (CAD) burden shown
on coronary computed tomographic angiog-
raphy (CTA) predicts future cardiac events
and death (1–3). Although studies have shown that
the presence and severity of calcified coronary
atherosclerosis visualized using coronary artery cal-
cium testing in asymptomatic patients are associated
with significant changes in cardiovascular preventive
medication prescribing patterns and improvements in
cardiovascular risk factors (4,5), similar studies re-
porting the impact of CAD visualized on CTA are
limited (6–9). For any imaging modality to ulti-
See page 582
mately result in improved outcomes, patient man-
agement and behavior must be significantly affected
and potentially guided in intensity by the results of
the test. Because both obstructive and nonobstruc-
tive CAD on CTA are associated with a substantial
increase in adverse event rates (2), providers may
elect to intensify cardiovascular preventive medica-
tions for CAD visualized on CTA; however, the
magnitude of these changes and their effect on
cardiovascular risk factors as related to CTA disease
severity is largely unknown. This is particularly
important because a significant proportion of pa-
tients undergoing coronary CTA according to ap-
propriate use criteria will have subclinical nonob-
structive CAD, leaving providers with questions on
how to optimally treat these patients, especially
those at low risk according to standard global risk
scores (10). We compared pre- and post-CTA
prescription patterns of aspirin, statin, and antihy-
pertensive medications, and subsequent changes in
serum cholesterol and blood pressure (BP) mea-
sures, stratified according to CAD severity among
patients clinically referred for coronary CTA.
M E T H O D S
Study population. We retrospectively identified
,125 consecutive adult patients without known
AD who underwent coronary CTA between May
006 and December 2010 for possible angina at
alter Reed Army Medical Center. Previous CAD
as defined as history of a myocardial infarction
MI), coronary revascularization, or diagnosis of
bstructive (50% stenosis) CAD. Patient demo-
raphic information, medical history, medications
t the time of CTA, test indication, scan parame-
ers, and CTA findings were prospectively col-ected. Hypertension was defined as a documented
istory of high BP or treatment with antihyperten-
ive medications. Diabetes mellitus was defined by
iagnosis of diabetes made previously by a physician
nd/or use of insulin or oral hypoglycemic agents.
yslipidemia was defined as known but untreated
yslipidemia or treatment with lipid-lowering
edications. Current smoking was defined as any
igarette use within the past month. Family
istory of early CAD was defined as clinically
anifest CAD involving a male first-degree rel-
tive younger than 55 years of age or a female
rst-degree relative younger than 65 years of age.
ndividual 10-year risk of MI and coronary death
as calculated using the Framingham risk score
11). The study was approved by the local insti-
utional review board.
Coronary CTA. According to institutional protocol,
ll patients were prescribed variable doses (typically
0 to 100 mg) of oral metoprolol to be taken 1 h
efore the scheduled scan. Intravenous
etoprolol was administered as needed
efore coronary CTA to obtain a goal
re-scan heart rate of 65 beats/min.
itroglycerin 0.4 to 0.8 mg sublingual was
iven 1 min before contrast image acqui-
ition. All patients were in sinus rhythm.
oronary CTA studies were performed
ith a 64-slice computed tomography
canner system (LightSpeed VCT, GE
ealthcare, Waukesha, Wisconsin) in ac-
ordance with published guidelines (12).
oronary CTA scans were interpreted
ointly (consensus) by a cardiologist and
adiologist, each level 2 or 3 certified in the inter-
retation of coronary CTA (13). Coronary lesions
ere characterized according to institutional proto-
ol by the maximal luminal diameter stenosis as
one (no atherosclerosis and no stenosis), mild
atherosclerosis with 0% to 49% stenosis), moderate
50% to 69%), and severe (70% to 100%) in 1
ajor epicardial vessel.
Outcomes. After coronary CTA, comprehensive
prescription, laboratory data, and clinical follow-up
information (including death) were queried by an
independent data extractor, blinded to the coronary
CTA results and baseline risk factors, using all
available electronic health databases (inpatient, out-
patient, laboratory, radiological) of the Department
of Defense Military Healthcare System, a large
closed international health care network providing
comprehensive and accessible health care and access
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576To evaluate changes in CAD medications attrib-
uted to coronary CTA findings, pre- and post-CTA
aspirin, statin, and BP medication prescriptions were
retrospectively queried using the Department of De-
fense worldwide pharmacology database to include
any prescriptions in the 6 months before and 6
months immediately after coronary CTA. Medica-
tion assessment was done for all patients at least 6
months after coronary CTA by investigators
blinded to CTA findings. Changes in therapy were
defined as no change, less intensive, or more inten-
sive treatment. Intensification of therapy was de-
fined as the initiation of aspirin, initiation or in-
crease in the BP medication dose, and/or the
initiation or increase in the dose of a statin or
change to a more potent statin preparation based on
the expected percentage of low-density lipoprotein
cholesterol (LDL-C) decrease (14,15). Indepen-
dent associations of pre- and post-CTA medication
use were performed adjusting for baseline medica-
tion use and CAD risk factors (age, sex, hyperten-
sion, diabetes, tobacco use, and dyslipidemia), and
results were stratified by CAD severity on CTA,
defined as no CAD, nonobstructive (50% steno-
sis), and obstructive CAD (50%).
To evaluate the control of traditional CAD risk
factors pre- and post-CTA, systolic and diastolic BP
values and lipid profiles were queried in a similar
blinded fashion to include total, LDL-C, and high-
density lipoprotein cholesterol. The most recent lipid
profile in the 12 months pre-CTA (mean 1.6  1.6
months) was compared with the most recent available
post-test lipid profile 4 weeks, but 12 months,
post-CTA (mean 6.3  4.5 months) to allow ade-
quate time to permit meaningful changes in choles-
terol values in a manner consistent with previous
research (7). Similarly, the most recent BP results in
the 12 months pre-CTA (mean 1.5  1.7 months)
were compared with the most recent BP measure 4
weeks, but 12 months, post-CTA (mean 3.7  2.3
months). When BP readings were available from 2
separate visits, the mean was used from the 2 most
recent visits.
Major adverse cardiac events were assessed to
include combined rates of death from any cause,
MI, and coronary revascularization, with results
stratified by CAD severity on CTA. Nonfatal MI
was ascertained by a review of clinical notes for a
diagnosis of MI and confirmed using the World
Health Organization definition (16). Revasculariza-
tion was defined as coronary artery bypass graft
surgery or percutaneous coronary intervention 90
days from coronary CTA. Revascularizations 90days from coronary CTA were censored because
previous studies demonstrated that these interven-
tions are performed based on the results of the
index coronary CTA, whereas coronary revascular-
izations 90 days from coronary CTA were con-
sidered to be new events related to disease worsen-
ing (17). The Social Security Death Index was
screened to ensure no deaths were missed, and
clinical outcomes were adjudicated independently
by 2 cardiologists who were unaware of coronary
CTA results and changes in medications.
Statistical analysis. Continuous variables with normal
distributions were expressed as mean  1 SD and
compared with the Student t test for independent
groups and 1-way analysis of variance for between-
group comparisons. Categorical variables were ex-
pressed as frequencies (%) and compared by Pearson
chi-square test. A 2-tailed p value 0.05 was consid-
ered significant. Changes in medication use from pre-
to post-CTA (dependent variable) were assessed using
multivariable logistic regression adjusting for covariate
pretest medication use and baseline CAD risk factors
(age, sex, hypertension, diabetes, and dyslipidemia). A
linear mixed-effects model was used to evaluate for
changes in continuous dependent variables pre- and
post-CTA, with subjects and pre- and post-coronary
CTA status as random effects, and medication inten-
sification and CTA severity (no CAD,50%,50%)
s fixed effects (18). All analyses were performed with
PSS for Windows (version 19.0, SPSS Inc., Chi-
ago, Illinois) and Stata (version 12.1, StataCorp,
ollege Station, Texas).
R E S U L T S
Patient characteristics. Baseline patient characteris-
ics are displayed in Table 1. Patients (N  1,125)
were of mean age 50  12 years, 59% men, and
were followed for a mean period of 24  13
months. The group was predominantly low risk
(mean Framingham risk score, 4.5  5.5%), with
33%, 34%, and 47% taking aspirin, statin, and BP
treatment at baseline, respectively. Baseline signif-
icant differences in patients with no CAD, 50%
stenosis, and 50% stenosis were present, where
increasing CAD severity on coronary CTA was
associated with increased cardiovascular risk factors;
greater likelihood of baseline aspirin, statin, and BP
medication use; and significant differences in base-
line HDL-C and systolic BP. A significant portion
of patients with nonobstructive and obstructive
CAD were not taking aspirin (55% and 45%,
respectively), a statin (55% and 31%, respectively),
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577or BP medication (43% and 36%, respectively) at
the time of coronary CTA. On the basis of worst
stenosis in any coronary segment, 54.8% of patients
(n  617) had no CAD, 36.5% (n  411) had
nonobstructive CAD (50% stenosis), and 8.6%
(n  97) had obstructive CAD (50% stenosis).
Outcomes. Compared with those with no CAD,
atients with nonobstructive and obstructive CAD
emonstrated significant intensification in aspirin
9% no CAD, 29% nonobstructive CAD, and 40%
bstructive CAD; p  0.001), statin (26%, 46%,
nd 46% of patients; p  0.001), and BP medica-
ion (11%, 21%, and 24%; p  0.001) (Table 2,
nline Fig. 1). Controlling for baseline risk factors
nd medication use, CAD severity was indepen-
ently associated with aspirin and statin use in
atients with nonobstructive CAD (odds ratio
OR]: 6.91, 95% confidence interval [CI]: 4.69 to
0.20; OR: 6.58, 95% CI: 3.02 to 14.33; p  0.001
or aspirin and statin, respectively) and obstructive
AD (OR: 42.44, 95% CI: 15.81 to 113.89, p 
.001; OR: 30.35, 95% CI: 3.18 to 289.23; p 
.003), and with BP medication use in patients with
onobstructive CAD (OR: 1.57, 95% CI: 1.10 to
.24; p  0.013) (Fig. 1). Absolute rates of all
herapies significantly increased post-CTA in pa-
ients with nonobstructive and obstructive CAD
Table 1. Baseline Patient Characteristics
All Patients
(N  1,125)
N
(n
Age, yrs 50 12 4
Follow-up, months 24 13 2
Men 59
Body mass index, kg/m2 29 5 2
Hypertension 49
Hyperlipidemia 51
Diabetes mellitus 10
Family history of CAD 27
Tobacco use in past 30 days 12
Total cholesterol (n  841), mg/dl 191 38 19
LDL cholesterol (n  1,068), mg/dl 115 33 11
HDL cholesterol (n  1,068), mg/dl 52 17 5
Systolic BP (n  1,002), mm Hg 127 14 12
Diastolic BP (n  1,002), mm Hg 79 8 7
Framingham risk score (10 yr CHD) 4.5 5.5 2
Typical angina 8
Aspirin use 33
Statin use 34
BP medication use 47
Values are mean  1 SD or %.
BP  blood pressure; CAD  coronary artery disease; CHD  coronary heartTable 2).Complete pre- and post-CTA measurements of
otal, LDL-C, and high-density lipoprotein choles-
erol were available in 37% of patients (n  412).
re- and post-CTA systolic and diastolic BP mea-
urements were available in 85% of patients (n 
59). When BP readings were available from 2
eparate visits before or after CTA, the mean was
D
17)
<50% Stenosis
(n  411)
>50% Stenosis
(n  97) p Value
12 55 10 58 10 0.001
13 24 13 26 15 0.23
65 74 0.001
5 29 5 29 5 0.86
59 73 0.001
64 89 0.001
14 20 0.001
29 23 0.77
13 17 0.41
38 189 39 181 38 0.08
31 116 35 108 33 0.08
18 50 15 46 14 0.001
14 129 14 130 13 0.001
8 79 9 78 8 0.82
3.7 6.2 6.1 8.5 7.6 0.001
6 14 0.045
45 55 0.001
45 69 0.001
52 56 0.001
se; HDL  high-density lipoprotein; LDL  low-density lipoprotein.
Table 2. Unadjusted Medication Rates Pre- Versus Post-Coronar
No CAD
(n  617)
<50% Stenosis
(n  411)*
>50%
(n
Statin pre-CTA 21 45
Less intensive 18 10
Statin started 6 24
More intensive† 26 46
Statin post-CTA 21 60
BP medication pre-CTA 32 52
Less intensive 1 1
BP medication started 3 4
More intensive† 11 21
BP medication post-CTA 35 56
Aspirin pre-CTA 21 45
Aspirin stopped 5 1
Aspirin started 9 29
Aspirin post-CTA 25 73
Values are %. *p  0.05 comparing unadjusted rates of pre- versus p
†Intensiﬁcation deﬁned as initiation or increase in dose of a medication or, in t
change to more potent statin.o CA
 6
6
4
53
9
39
36
6
26
11
3
6
5
5
8
.7
8
21
21
32y CTA
Stenosis
 97)* p Value
69 0.001
4 0.001
24 0.013
46 0.001
86 0.001
56 0.001
1 0.99
9 0.001
24 0.001
64 0.001
55 0.001
0 0.001
40 0.001
95 0.001
ost-CTA medication use.
he case of statin therapy,CTA  computed tomographic angiography; other abbreviations as in Table 1.
Cp
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578used of the most recent measurements; at least 2
BP results were available for 916 of 959 patients
before CTA and in 852 of 959 patients after
CTA.
Comparing pre- and post-CTA cardiovascular
risk factor control, relative to patients with no
CAD, patients with 50% and 50% stenosis
demonstrated significant improvements in total
cholesterol (no CAD, 6.7 mg/dl; nonobstructive
AD,14.7 mg/dl; obstructive CAD,24.7 mg/dl;
p  0.008), LDL-C (5.6, 14.1, 24.6 mg/dl;
BP med post-CTA
≥50% Stenosis 1.30 (0.73 - 2.35) 
<50% Stenosis 1.57 (1.10 - 2.24) 
Statin post-CTA
≥50% Stenosis 30.35 (3.18 - 289.23) 
<50% Stenosis 6.58 (3.02 - 14.33) 
ASA post-CTA
≥50% Stenosis 42.44 (15.81 - 113.89) 
<50% Stenosis 6.91 (4.69 - 10.20) 
Medication Adjusted OR (95% CI) 
0.1
Figure 1. Adjusted Post-CTA Medication Use Stratiﬁed by CAD
Controlling for baseline medication use and coronary artery disease
dyslipidemia), CAD severity demonstrated on coronary computed to
aspirin (ASA), statin, and blood pressure (BP) medication use in pat
patients with obstructive CAD. Horizontal lines represent 95% conﬁ
5.0
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Figure 2. Mean Change in Cholesterol Values After Coronary CT
Relative to patients with no CAD, patients with 50% and 50% s
and low-density lipoprotein cholesterol (LDL-C), but no change in h
*p  0.05 versus no CAD. Abbreviations as in Figure 1. 0.001) (Fig. 2), systolic BP (0.1, 1.4, 4.9
mm Hg; p 0.002), and diastolic BP (0.6, 1.0,
3.4 mm Hg; p 0.012) (Fig. 3). When compared
with patients with no change in medical therapy, a
significant improvement in total cholesterol and
systolic BP were noted in patients with both non-
obstructive and obstructive CAD when therapy was
intensified (Fig. 4).
During 24  13 month follow-up, there were 6
deaths, 3 MIs, and 6 late coronary revasculariza-
tions. There was 1 event in the no CAD group
0.378
0.013
0.003
<0.001
<0.001
<0.001
p Value
.0 10.0 100.0 1000.0
rity
D) risk factors (age, sex, hypertension, diabetes, tobacco use, and
graphic angiography (CTA) was independently associated with
with nonobstructive CAD and with aspirin and statin use in
ce intervals (CIs). OR  odds ratio.
HDL-C
*
No CAD
<50% Stenosis
≥50% Stenosis
sis demonstrated signiﬁcant improvements in total cholesterol
density lipoprotein cholesterol (HDL-C) after coronary CTA.1
Seve
(CA
mo
ients-C
A
teno
igh-
viat
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 6 , N O . 5 , 2 0 1 3
M A Y 2 0 1 3 : 5 7 4 – 8 1
Cheezum et al.
Changes in Medications and Risk Factors After CTA
579(0.08%/year), 4 events in the nonobstructive
group (0.5%/year), and 10 events in patients with
obstructive CAD (4.3%/year) (p  0.001). Due
to low event rates, an analysis of the impact of
medication changes on adverse events was under-
powered.
D I S C U S S I O N
In this study, the largest reported to date to examine
the relationship of CAD demonstrated on coronary
CTA to changes in medication use and measured
risk variables, we observed that the presence and
severity of CAD on coronary CTA were indepen-
dently associated with intensification of aspirin,
statin, and antihypertensive medications within 6
months after CTA among a low-risk symptomatic
cohort. These changes in provider prescribing pat-
terns were associated with significant improvements
in total cholesterol, LDL-C, and BP measures.
Importantly, the absence of CAD was not associ-
ated with significant changes in cardiovascular pre-
ventive medication use.
Our results from a low-risk, symptomatic cohort
with a low prevalence of obstructive CAD (8%)
suggest that providers may be initiating and adjust-
ing cardiovascular preventive therapies based on
coronary CTA findings and beyond that indicated
by baseline risk factor burden. In contrast, Ha-
chamovitch et al. (9) prospectively compared base-
1.0
0.0
-1.0
-2.0
-3.0
-4.0
-5.0
-6.0
m
m
 H
g
Systolic BP
*
*
Figure 3. Mean Change in BP Values After Coronary CTA
Relative to patients with no CAD, patients with 50% and 50%
diastolic BP after coronary CTA. *p  0.05 versus no CAD. Abbreline and post-imaging medication rates of patientsat intermediate to high pre-test likelihood for CAD
referred for single-photon emission computed to-
mography (n  565), positron emission tomogra-
phy (n  548), or coronary CTA (n  590).
Although medical therapy increased proportionally
to the degree of abnormal noninvasive test findings,
the authors concluded that there was significant
undertreatment of patients with high-risk imaging
findings across all modalities during 90-day follow-
up. Specifically, among patients with the most
severe test abnormalities, 20% to 30% did not
receive aspirin and 20% to 25% did not receive a
lipid-lowering agent at 90 days after the index test.
The discrepancy between the higher prescription
rates observed in our population versus the lower
rates seen in their higher risk cohort may be, in part,
attributable to fewer comorbidities in our popula-
tion allowing for fewer contraindications to medi-
cations, use of filled prescriptions as opposed to
patient interviews to measure medication changes,
more complete prescription and health care cost
coverage, and complete in-hospital and within-
network referral sources where referring providers
are systematically provided direct, electronic CTA
reports. In the current health care cost environ-
ment, it is important to examine the association of
noninvasive cardiovascular test results with subse-
quent changes in medical treatment in the context
of socioeconomic factors and access to medical care
stolic BP
*
*
No CAD (n = 516)
<50% Stenosis (n = 355)
≥50% Stenosis (n = 88)
nosis demonstrated signiﬁcant improvements in systolic and
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580geneous follow-up related to health care system dif-
ferences. This hypothesis requires further study.
Numerous trials have demonstrated important
reductions in adverse event rates in the treatment of
modifiable CAD risk factors (15,19). In the absence
of long-term outcomes and cost-effectiveness data,
debate endures as to whether changes in preventive
medication therapies are justified based on CTA
findings alone, particularly in patients with nonob-
structive CAD at low global cardiovascular risk
(20,21). We observed that nonobstructive CAD
was associated with significant intensification in
cardiovascular preventive therapies among a low-
risk symptomatic cohort. Although the mainstay of
cardiovascular risk reduction is and should remain
therapeutic lifestyle modification, trials are needed
to assess the long-term impact of aspirin and statin
therapies on patients with CAD, particularly non-
obstructive CAD, diagnosed using coronary CTA,
perhaps accounting for measures of plaque risk
(e.g., degree of vessel remodeling or presence of
low-attenuation plaque) (22).
Study limitations. We recognize several limitations
o our study. The study was retrospective, per-
ormed at a single center, and underpowered to
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Figure 4. Effect of Medication Intensiﬁcation on Changes in Tot
CAD Severity on Coronary CTA
Compared with patients with no change in medical therapy, signiﬁ
patients with nonobstructive and obstructive CAD when medical th
vals. *p values shown for in-group and between-group comparisonssess for the effect of medication changes on cutcomes. Due to the observational nature of our
nalysis, follow-up for measured post-test risk
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